Results 51 to 60 of about 179,831 (305)

In-depth analysis of the safety of CAR-T cell therapy for solid tumors

Frontiers in Immunology
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy.
Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiexiong Wu, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Ting Su, Ting Su, Ting Su, Ting Su, Ting Su, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +33 more
doaj   +1 more source

Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

BMC Cancer, 2018
Background Salivary gland cancers are not sensitive to conventional radiotherapy or chemotherapy regimens. Therefore, the development of a new treatment strategy is of critical importance for improving the prognosis.
Yuji Makita, Naoki Kunii, Daiju Sakurai, Fumie Ihara, Shinichiro Motohashi, Akane Suzuki, Toshinori Nakayama, Yoshitaka Okamoto   +7 more
doaj   +1 more source

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. [PDF]

, 2017
INTRODUCTION: Colorectal cancer remains the second leading cause of cancer death in the United States, and new strategies to prevent, detect, and treat the disease are needed.
Aka, Allison A., Pattison, Amanda M., Rappaport, Jeff A., Sato, Takami, Snook, Adam E., Waldman, Scott A.   +5 more
core   +2 more sources

Targeting the tumor microenvironment in colorectal peritoneal metastases

, 2020
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim, De Wever, Olivier, Heriot, Alexander G., Narasimhan, Vignesh, Ramsay, Robert G.   +4 more
core   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Chimeric antigen receptor–engineered T cells for liver cancers, progress and obstacles

Tumor Biology, 2017
Chimeric antigen receptor–engineered T cells therapy has become the hottest topic of immunotherapy, as its great successes achieved in treating refractory hematological malignancies.
Keyu Li, Yaliang Lan, Jiabei Wang, Lianxin Liu   +3 more
doaj   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

CAR-T cell. the long and winding road to solid tumors [PDF]

, 2018
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the "next generation" of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment ...
A Heczey, AH Long, AM Leen, AP Cogdill, ARW Schröder, B Clémenceau, B Moldt, BD Koster, C Carpenito, C Zhang, CE Brown, CH June, CM Bollard, D Kobelt, DM Frey, DM Pardoll, DM Shayakhmetov, DW Lee, EI Buchbinder, EJ Lipson, EM Allen Van, F Bushman, F Ochi, F You, FS Hodi, G Gross, G Sconocchia, G Sconocchia, GL Beatty, H Karlsson, H Koehler, H Torikai, HC Ertl, HJ Pegram, I Caruana, J Badhiwala, J Ellis, J Wang, JE Bakema, JH Sampson, JL Tanyi, K Kono, K Kono, K Kudo, K Tamada, K Töpfer, KC Feng, L Bracci, L Zhang, LE Kandalaft, LM Rogers, LM Whilding, M Chmielewski, M Hegde, M Koneru, M Palma De, M Sadelain, M Sadelain, MA Ligtenberg, MC Milone, MCI Schalkwyk van, MD Stewart, ME Mikucki, ME Weijtens, MJ Besser, MJ Besser, MJ Butte, MJ Osborn, ML Davila, ML Davila, MM D’Aloia, MV Maus, N Ahmed, N Ahmed, O Walisko, P Kebriaei, PB Hackett, PC Schuberth, R Braster, R Monjezi, RA Morgan, RA Morgan, RJ Brentjens, RP Junghans, S Chabot, S Mohammed, S Nayak, S Sakaguchi, S Su, S Toyokuni, S Wilkie, SA Richman, SC Katz, SL Goff, SL Maude, SR Witting, SV Kulemzin, TR Medler, TR Simpson, V Arumugam, VD Fedorov, VD Sadelain, W Wang, XS Zhong, Z Eshhar, Z Grada, Z Wang   +106 more
core   +2 more sources

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source

Identification of functional murine mitochondrial formyl peptides and their effects on myeloid‐derived suppressor cell generation

FEBS Open Bio, EarlyView.
We first identified functional murine mitochondrial N‐formyl peptides (MT‐FPs) and investigated their effects on the in vitro myeloid‐derived suppressor cell (MDSC) generation from bone marrow cells. We demonstrated that MT‐FPs acted directly on bone marrow cells to promote MDSC generation and modulated the polymorphonuclear (PMN)‐MDSC/monocyte (M ...
Miyako Ozawa, Saori Kagoshima, Akira Yamada   +2 more
wiley   +1 more source